- Home
- Equipment
- canada ontario
- phase 1 clinical
Show results for
Refine by
Applications
- Microbiome Therapeutics for Patients and Physicians
- Vaccine for COVID-19
- BSD-2000 - Deep Regional Hyperthermia System for Clinical
- Medical cannabis solutions for regulatory pathway sector
- Medical cannabis solutions for mental health costs sector
- IONICON PTR-TOF instruments deployed for COVID-19 detection in breath
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiota for Restoration Therapy
- Microbiota Based Product for Physician-Sponsored Studies
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Liquid Biopsy Technology for Hereditary Cancer Screening
Phase 1 Clinical Equipment & Supplies In Canada Ontario
132 equipment items found
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
BlueWillow’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies using a seasonal influenza vaccine. Several other ongoing BlueWillow programs — including intranasal vaccines for anthrax, pandemic influenza, RSV, HSV-2 and chlamydia — have recently advanced through successful ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a cancer ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response in participants ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study is completed to confirm the predictions in patients with metastatic colorectal cancer (NCT03391232, Hubbard et al ASCO 2020). ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. FB6001 is expected to be ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 clinical trial demonstrated that our Ebola GP ...
Manufactured by:Sequoia Vaccines, Inc. based inSaint Louis, MISSOURI (USA)
Sequoia is developing a vaccine to reduce the recurrences of Urinary Tract Infections (UTI). Sequoia has completed its first clinical study in women with and without a history of recurrent UTI. In this study, Sequoia's investigational vaccine was highly immunogenic and well tolerated. In addition, it appears that the vaccine may indeed reduce the frequency of UTI. These ...
Manufactured by:Ocean Biomedical based inProvidence, RHODE ISLAND (USA)
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Like Meissa’s RSV vaccine candidate, MV-014-212 offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce mucosal and systemic immunity, as well as a straightforward, economical, and scalable manufacturing process. A Phase 1 clinical study has been ...
Manufactured by:Kalaris based inWaltham, MASSACHUSETTS (USA)
Kalaris Therapeutics is focused on developing innovative treatments for retinal diseases, aiming to reduce the burden of frequent clinical visits for patients with retinal neovascular and exudative conditions. Their lead product, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery as an anti-VEGF agent. TH103 functions as a soluble decoy ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX14, recombinant anti-RANKL human monoclonal antibody injection, a denosumab biosimilar. It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in women with high fracture ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
A fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus ...
Manufactured by:Triple Hair Inc. based inDieppe, NEW BRUNSWICK (CANADA)
This innovative triple combination therapy promotes hair regrowth in men with androgenic alopecia. Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making hair thicker and darker. The effectiveness of this revolutionary solution was proven in the first two phases of clinical trials, where participants all ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
The iMouse DigiFrame offers a sophisticated solution for researchers looking to digitize rodent home-cage monitoring systems without disrupting existing setups. It is designed to retrofit onto current rack systems, providing continuous 24/7 observation capabilities. This system incorporates high-resolution infrared cameras with a dual-spectrum light system to ensure artifact-free imaging during ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under cGMP conditions. It is produced under cGMP conditions from pure, clonal ...